Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:2407:315-331.
doi: 10.1007/978-1-0716-1871-4_21.

Ex Vivo Differentiation of Resting CD4+ T Lymphocytes Enhances Detection of Replication Competent HIV-1 in Viral Outgrowth Assays

Elizabeth R Wonderlich  1 , Monica D Reece  2 , Deanna A Kulpa  3
Affiliations

Ex Vivo Differentiation of Resting CD4+ T Lymphocytes Enhances Detection of Replication Competent HIV-1 in Viral Outgrowth Assays

Elizabeth R Wonderlich et al. Methods Mol Biol. 2022.

Abstract

Quantifying the number of cells harboring inducible and replication competent HIV-1 provirus is critical to evaluating HIV-1 cure interventions, but precise quantification of the latent reservoir has proven to be technically challenging. Existing protocols to quantify the frequency of replication-competent HIV-1 in resting CD4+ T cells from long-term ART treated individuals have helped to investigate the dynamics of reservoir stability, however these approaches have significant barriers to the induction of HIV-1 expression required to effectively evaluate the intact reservoir. Differentiation of CD4+ T cells to an effector memory phenotype is a successful strategy for promoting latency reversal in vitro, and significantly enhances the performance and sensitivity of viral outgrowth assays.

Keywords: HIV-1; HIV-1 reservoir; Resting CD4+ T lymphocytes.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient Study investigators. N Engl J Med 338(13):853–860 - DOI - PubMed
    1. Garrigue I, Pellegrin I, Hoen B, Dumon B, Harzic M, Schrive MH, Sereni D, Fleury H (2000) Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA. AIDS 14(18):2851–2855 - DOI - PubMed
    1. Garner SA, Rennie S, Ananworanich J, Dube K, Margolis DM, Sugarman J, Tressler R, Gilbertson A, Dawson L (2017) Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations. J Virus Erad 3(2):82–84 - DOI - PubMed - PMC
    1. International ASSWGoHIVC, Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Di Mascio M, Katlama C, Lafeuillade A, Landay A, Lederman M, Lewin SR, Maldarelli F, Margolis D, Markowitz M, Martinez-Picado J, Mullins JI, Mellors J, Moreno S, O’Doherty U, Palmer S, Penicaud MC, Peterlin M, Poli G, Routy JP, Rouzioux C, Silvestri G, Stevenson M, Telenti A, Van Lint C, Verdin E, Woolfrey A, Zaia J, Barre-Sinoussi F (2012) Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12(8):607–614. https://doi.org/10.1038/nri3262 - DOI
    1. Horsburgh BA, Palmer S (2018) Measuring HIV persistence on antiretroviral therapy. Adv Exp Med Biol 1075:265–284. https://doi.org/10.1007/978-981-13-0484-2_11 - DOI - PubMed

Publication types

LinkOut - more resources